Monitor enrollment progress in the Phase 2 UC trial as a key catalyst; assess whether the Iterative Health partnership meaningfully accelerates timelines. The $3M raise provides limited runway, so future financing needs should be watched.
Price Chart
Executive Summary
Palisade Bio issued 1.54 million shares to an affiliate of Iterative Health for $3.0 million to support a clinical trial partnership for its ulcerative colitis drug PALI-2108. The company also entered into a master services agreement with Iterative Health to accelerate patient enrollment in the upcoming Phase 2 study.
Key Facts
- Palisade Bio issued 1,536,885 shares of common stock to an affiliate of Iterative Health for $3.0 million ($1.952 per share)
- Proceeds support collaboration with Iterative Health to expedite patient enrollment in the Phase 2 study of PALI-2108 for moderate to severe ulcerative colitis
- The share issuance was conducted under a private placement exempt from registration under Section 4(a)(2) of the Securities Act
- The transaction represents approximately 4.9% of Palisade Bio's current market cap of $312M
Financial Impact
$3.0 million in gross proceeds from issuance of 1.54 million shares at $1.952 per share, representing 4.9% dilution based on current market cap
Risk Factors
- Dilution from share issuance may pressure stock price
- Clinical trial delays or poor enrollment despite partnership
- Limited funding size suggests need for additional capital in near term
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-014822 |
| Document: 0001493152-26-014822-index-headers.html | 0001493152-26-014822 |
| Document: 0001493152-26-014822-index.html | 0001493152-26-014822 |
| Document: 0001493152-26-014822.txt | 0001493152-26-014822 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $2.14 $2.05 | ▼ −4.21% | ▼ −3.15% | $1.45 (−32.48%) |
Jul 10, 2026 11w ago | Insider Cluster | $1.89 $2.10 | ▲ +11.11% | ▲ +7.93% | $1.45 (−23.54%) |
Jul 8, 2026 12w ago | Insider Cluster | $1.97 $2.09 | ▲ +6.09% | ▲ +3.85% | $1.45 (−26.65%) |
Jun 11, 2026 16w ago | 8-K | $1.71 $1.96 | ▲ +14.62% | ▲ +12.84% | $1.45 (−15.50%) |
May 22, 2026 19w ago | EFFECT | $1.95 $1.89 | ▼ −3.08% | ▼ −1.66% | $1.45 (−25.90%) |
May 12, 2026 20w ago | S-3 | $1.87 $1.78 | ▼ −4.81% | ▼ −4.20% | $1.45 (−22.73%) |
Apr 29, 2026 22w ago | DEFA14A | $2.00 $2.12 | ▲ +6.00% | ▲ +0.77% | $1.45 (−27.75%) |
Apr 2, 2026 26w ago | 8-K | $1.89 $2.00 | ▲ +5.82% | ▼ −4.06% | $1.45 (−23.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access